Excision BioTherapeutics develops CRISPR-based antiviral therapies designed to eliminate viral genomes from infected patients. Its lead candidate, EBT-101, is being advanced into a Phase 1/2 clinical trial for people with chronic HIV infection. The company also supports preclinical programs including EBT-103 targeting JC virus (PML), EBT-104 for herpes simplex virus, and EBT-107 for hepatitis B. Excision says it has demonstrated a functional cure for HIV in animal models and is developing technologies and IP originating at Temple University and UC Berkeley. The company is located in San Francisco and plans to use recent financing to build team and infrastructure to progress its programs. Management states the work aims to deliver potentially curative therapies to patients with chronic viral infections. Excision BioTherapeutics develops advanced gene-editing therapeutics aimed at treating and eradicating life-threatening diseases caused by neurotropic viruses. Its core product is an HIV-1-targeted CRISPR platform designed to fully remove/excise the HIV-1 genome from all human cells and tissues. The company plans to use this platform to enter human clinical trials and to extend the approach to other viruses by targeting and eliminating their genetic elements. Excision completed a $10M seed financing led by ARTIS Ventures to support these efforts. The company was founded in 2015 out of Temple University’s Lewis Katz School of Medicine in Philadelphia, PA. It is led by founder, president and CEO Thomas Malcolm, Ph.D., and its founding team includes Kamel Khalili, Ph.D., Rob Simmons and David Rowe.

Total raised

$70M

Funding rounds

2

Latest round

Equity

Latest activity

Feb 2021